Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.64 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975192 | 1.00 | EPHX1 (0.64) | EPHX1ANPEPALPIPKMPTGS1 | |
| SCHEMBL11947633 | 1.00 | EPHX1 (0.64) | EPHX1ANPEPALPIPKMPTGS1 | |
| SCHEMBL24312004 | 0.89 | EPHX1 (0.50) | EPHX1ANPEPPTGS1TAAR1 | |
| SCHEMBL10273446 | 0.82 | SLC6A4 (0.42) | EPHX1ANPEPMAOASLC6A4 | |
| SCHEMBL9675566 | 0.81 | SLC15A1 (0.53) | EPHX1ANPEPALPIPKMPTGS1 | |
| SCHEMBL10051068 | 0.80 | ANPEP (0.49) | EPHX1ANPEPTAAR1CYP2A6 | |
| SCHEMBL10051066 | 0.80 | SLC6A4 (0.67) | EPHX1ANPEPSLC6A2TAAR1SLC6A4 | |
| SCHEMBL10051064 | 0.80 | ANPEP (0.49) | EPHX1ANPEPTAAR1CYP2A6 | |
| SCHEMBL19004026 | 0.80 | ANPEP (0.49) | EPHX1ANPEPTAAR1CYP2A6 | |
| SCHEMBL19003879 | 0.80 | SLC6A4 (0.67) | EPHX1ANPEPSLC6A2TAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9999609-B2 | Methods for treating or preventing fatigue | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-06-19 | — | — | US | disclosed |
| US-20170000756-A1 | METHODS FOR TREATING OR PREVENTING FATIGUE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-01-05 | — | — | US | disclosed |
| US-9464041-B2 | Methods for treating or preventing fatigue | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-10-11 | — | — | US | disclosed |
| US-20140243406-A1 | Methods for Treating or Preventing Fatigue | SK Biopharmaceuticals, Co., Ltd. (KR) | 2014-08-28 | — | — | US | disclosed |
| US-8741950-B2 | Methods for treating or preventing fatigue | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| US-8729120-B2 | Adjunctive therapy for depression | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8552060-B2 | Methods for treatment of sexual dysfunction | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-10-08 | — | — | US | disclosed |
| US-8440715-B2 | Treatment of sleep-wake disorders | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-05-14 | — | — | US | disclosed |
| US-8232315-B2 | Methods for treating drug addiction and improving addiction-related behavior | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-07-31 | — | — | US | disclosed |
| US-20120142769-A1 | METHODS FOR TREATING OR PREVENTING FATIGUE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-06-07 | — | — | US | disclosed |
| US-20100331332-A1 | METHODS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | SK HOLDINGS CO., LTD. (KR) | 2010-12-30 | — | — | US | disclosed |
| US-20090312416-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | SK HOLDINGS CO., LTD. (KR) | 2009-12-17 | — | — | US | disclosed |
| US-20090221553-A1 | Methods for Treatment of Sexual Dysfunction | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-09-03 | — | — | US | disclosed |
| US-20080039529-A1 | Adjunctive Therapy for Depression | SK CORPORATION (KR) | 2008-02-14 | — | — | US | disclosed |
| WO-2007111994-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331332-A1 | METHODS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | CES2, SLC6A3, CHAT | EPHX1 2008/4885ANPEP 1999/4885ALPI 3857/4885 |
| US-20140243406-A1 | Methods for Treating or Preventing Fatigue | GSTO1, GSTA2, CPT1B | EPHX1 1266/4885ANPEP 2657/4885ALPI 684/4885 |
| US-20170000756-A1 | METHODS FOR TREATING OR PREVENTING FATIGUE | GSTO1, GSTA2, CPT1B | EPHX1 1266/4885ANPEP 2657/4885ALPI 684/4885 |
| US-20120142769-A1 | METHODS FOR TREATING OR PREVENTING FATIGUE | GSTO1, GSTA2, CPT1B | EPHX1 1266/4885ANPEP 2657/4885ALPI 684/4885 |
| US-20090312416-A1 | TREATMENT OF SLEEP-WAKE DISORDERS | HCRTR1, HCRTR2, MTNR1B | EPHX1 926/4885ANPEP 1958/4885ALPI 2212/4885 |
| US-20090221553-A1 | Methods for Treatment of Sexual Dysfunction | CYP17A1, GNRHR, HSD17B11 | EPHX1 1857/4885ANPEP 1932/4885ALPI 1962/4885 |
| US-20080039529-A1 | Adjunctive Therapy for Depression | CRH, TPH1, CRHR1 | EPHX1 3097/4885ANPEP 2814/4885ALPI 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.